Brief: Scynexis Inc Says FDA Determined Compassionate Use Program For Ibrexafungerp Can Continue

Scynexis

02/10/2023 16:37

Oct 2 (Reuters) - SCYNEXIS Inc  SCYX.O :
    * SCYNEXIS INC - FDA DETERMINED COMPASSIONATE USE PROGRAM
FOR
IBREXAFUNGERP CAN CONTINUE
    * SCYNEXIS INC - CLINICAL HOLD AND RECALL OF IBREXAFUNGERP
AFFECT
TWO ONGOING CLINICAL STUDIES: PHASE 3 MARIO STUDY AND A PHASE 1
LACTATION STUDY
    * SCYNEXIS INC - PATIENT LEVEL, CLINICAL PRODUCT RECALL OF
IBREXAFUNGERP HAS INITIATED, CO WORKING WITH VENDOR TO MANAGE
PROCESS

Further company coverage:  SCYX.O 

 ((Reuters.Briefs@thomsonreuters.com;))